SCHEMBL556206

SCHEMBL556206

CC1(C)CNC(C(=O)O)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.53
ALOX15 P16050 3/20 0.53
GRM2 Q14416 1/20 0.53
GRM3 Q14832 1/20 0.53
APLNR P35414 1/20 0.44
CYP2D6 P10635 3/20 0.39
CYP2C19 P33261 3/20 0.39
LMNA P02545 2/20 0.39
BLM P54132 2/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 1/20 0.39
THRB P10828 1/20 0.39
PMP22 Q01453 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.36
GRIA1 P42261 3/20 0.36
GRIA2 P42262 3/20 0.36
GRIA3 P42263 3/20 0.36
GRIA4 P48058 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18154922 1.00 CYP1A2 (0.53) CYP1A2ALOX15GRM2GRM3APLNR
SCHEMBL556207 1.00 CYP1A2 (0.53) CYP1A2ALOX15GRM2GRM3APLNR
Hydrochloric Acid SCHEMBL28529831 0.98 CYP1A2 (0.52) CYP1A2ALOX15GRM2GRM3APLNR
Hydrochloric Acid SCHEMBL15008250 0.98 CYP1A2 (0.52) CYP1A2ALOX15GRM2GRM3APLNR
Trifluoroacetic Acid SCHEMBL25227216 0.89 CYP1A2 (0.44) CYP1A2ALOX15GRM2GRM3APLNR
Hydrochloric Acid SCHEMBL29514375 0.84 CYP1A2 (0.47) CYP1A2ALOX15GRM2GRM3APLNR
SCHEMBL8270188 0.82 GRM2 (0.35) CYP1A2ALOX15GRM2GRM3APLNR
SCHEMBL3932250 0.80 CYP1A2 (0.52) CYP1A2ALOX15GRM2GRM3APLNR
SCHEMBL1268720 0.80 CYP1A2 (0.52) CYP1A2ALOX15GRM2GRM3APLNR
SCHEMBL23942121 0.80 CYP1A2 (0.52) CYP1A2ALOX15GRM2GRM3APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841257-B2 Inhibitors of STAT3 and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-09-23 US claimed
US-20120035114-A1 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-02-09 US claimed
WO-2010118309-A2 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-10-14 WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US claimed
WO-2025264645-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC. (US) 2025-12-26 WO disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
EP-4271676-A1 CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE Bionova Pharmaceuticals (Shanghai) Limited (CN) 2023-11-08 EP disclosed
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
US-11725008-B2 Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-15 US disclosed
EP-4214214-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 EP disclosed
WO-2001064678-A2 INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-09-07 WO disclosed
WO-2001002424-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE DU PONT PHARMACEUTICALS COMPANY (US) 2001-01-11 WO disclosed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US disclosed
EP-0787010-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-06 EP disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 WO disclosed
US-4977260-A Intermediates for preparing mono-, bi- and tricyclic amino acids HOECHST AKTIENGESELLSCHAFT (DE) 1990-12-11 US disclosed
US-4849524-A Process of preparing proline derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1989-07-18 US disclosed
US-4691022-A Process for the preparation of monocyclic, bicyclic and tricyclic aminoacids HOECHST AKTIENGESELLSCHAFT (DE) 1987-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS CYP1A2 1595/4885ALOX15 3381/4885GRM2 642/4885
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS CSNK1D, CSNK1A1, CSNK1G1 CYP1A2 2492/4885ALOX15 4090/4885GRM2 343/4885
US-11725008-B2 Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases PRMT1, PRMT5, PRMT3 CYP1A2 2668/4885ALOX15 4333/4885GRM2 971/4885
US-20120035114-A1 INHIBITORS OF STAT3 AND USES THEREOF STAT3, JAK2, STAT6 CYP1A2 4782/4885ALOX15 2409/4885GRM2 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.